Evidence map›Paper›PMID 33863783›Full record

RevieweNeuro

Trimetazidine Use in Parkinson's Disease: Is It a Resolved Problem?

Dávid Pintér, Dániel Bereczki, András Ajtay, Ferenc Oberfrank, József Janszky, Norbert Kovács

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in eNeuro. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Dávid PintérDepartment of Neurology, Medical School, University of Pécs, Pécs, Hungary 7623 david_pinter@outlook.com.ORCID 0000-0002-0734-6878
Dániel BereczkiDepartment of Neurology, Medical School, Semmelweis University, Budapest, Hungary 1085.
András AjtayDepartment of Neurology, Medical School, Semmelweis University, Budapest, Hungary 1085.
Ferenc OberfrankInstitute of Experimental Medicine, Budapest, Hungary 1083.
József JanszkyDepartment of Neurology, Medical School, University of Pécs, Pécs, Hungary 7623.
Norbert KovácsDepartment of Neurology, Medical School, University of Pécs, Pécs, Hungary 7623.
Resonance Research (United States) · USSemmelweis University · HUHUN-REN Institute of Experimental Medicine · HUUniversity of Pecs · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trimetazidine (TMZ), an antianginal drug, can worsen the symptoms of movement disorders, therefore, the European Medicines Agency (EMA) recommended avoiding the use of this drug in Parkinson's disease (PD). We investigated the impact of this recommendation on the observed trend of TMZ use in PD in Hungary from 2010 to 2016 by conducting a nationwide, retrospective study of health administrative data of human subjects. Interrupted time series analyses were performed to explore changes in user trends after the EMA recommendations. We found that TMZ use in PD decreased by 6.56% in each six-month interval after the EMA intervention [a change in trend of -530.22, 95% confidence interval (CI) = -645.00 to -415.44,

Indexed as

Parkinson DiseaseTrimetazidineAngina PectorisHumansRetrospective StudiesVasodilator AgentsTrimetazidineVasodilator Agentsangina pectorisEuropean Medicines Agencyinterrupted time series analysisParkinson’s diseasetrimetazidine

Identifiers

PMID33863783
PMCPMC8143021
OpenAlexW3152721842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.